Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma
- 84 Downloads
Although radioiodine has been applied in thyroid diseases including carcinoma for over 70 years, it was only in 1996 that the basic molecular mechanism of iodine uptake was identified. Iodide is actively transported into the thyroid via a membrane glycoprotein known as sodium iodide symporter (NIS). NIS mediates radioiodine uptake into thyroid normal and cancer cells. The knowledge on NIS expression has provided scientific background to the empirical management of thyroid carcinoma. Based on recent studies of the NIS gene, this paper provides current clinical applications and future studies.
KeywordsSodium iodide symporter NIS Thyroid cancer Gene therapy Theranostics
I thank all my teachers, family members, and friends who gave me endless encouragement and support for the successful completion of this project.
Compliance with Ethical Standards
Conflict of Interest
June-Key Chung, Hyun Woo Kim, Haewon Youn, and Gi Jeong Cheon declare no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 11.Barbara S. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.Google Scholar